Henoch-Schönlein purpura pathophysiology

Henoch-Schönlein purpura Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Henoch-Schönlein purpura from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Henoch-Schönlein purpura pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Henoch-Schönlein purpura pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Henoch-Schönlein purpura pathophysiology
CDC on Henoch-Schönlein purpura pathophysiology
Henoch-Schönlein purpura pathophysiology in the news
Blogs on Henoch-Schönlein purpura pathophysiology
Directions to Hospitals Treating Henoch-Schönlein purpura
Risk calculators and risk factors for Henoch-Schönlein purpura pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

• HSP is a small vessel leukocytoclastic vasculitis, but its pathophysiology is not completely understood.
• In patients with HSP the serum Ig-A levels are elevated, HSP is an immune complex-mediated disease with circulating immune complexes and IgA rheumatoid factors usually follows upper respiratory tract infections, various viruses, and the bacteria have been implicated as triggers of the disease.
• Patients with HSP have circulating Ig-A immune-complexes, patients with HSPN have an additional large molecular mass IgA1-IgG-containing circulating immune complexes.
• The IgA1 molecule has a hinge region containing up to six O-linked glycan chains[16,17] consisting of N-acetylgalactosamine, usually

with an attached β1,3-linked galactose.

• It has been reported that in patients with HSPN, the activity of β1,3-galactosyltransferase in peripheral B cells is reduced, leading to a lack of terminal β1,3-galactosyl residues in the hinge region of IgA1.
• The primary defect leading to the production of such abnormally glycosylated IgA1 is probably heritable.
• These aberrantly glycosylated IgA1 molecules have been shown to form immune complexes with IgG antibodies specific for galactose-deficient IgA1, thereby inhibiting the binding of the IgA molecules to hepatic receptors and avoiding their internalization and degradation by hepatic cells.
• This formation results in an increased amount of IgA immune complexes in circulation.
• The complexes may then deposit in renal mesangial areas and activate the complement system by the alternative or lectin pathways, which play a major role in the pathophysiology of this disease.
• Further, after depositing in the mesangium, the galactose-deficient IgA1 immune complexes activate mesangial cells.
• This results in the proliferation of cells such as macrophages and lymphocytes and the production of inflammatory and profibrogenic cytokines and

chemokines, which play a pivotal role in mesangial cell proliferation, matrix expansion, and inflammatory cell recruitment.

• There are also other possible pathogenetic mechanisms of HSPN, because throat cultures positive for group A beta-hemolytic streptococcus have been

found in 20%-30% of patients with HSPN, it is thought that nephritis-associated plasmin receptor, a group A streptococcal antigen, may also be responsible for some of the cases of HSPN.

• In addition, eosinophil activation and renal expression of alpha-smooth muscle actin have been reported to play a role in the

pathogenesis of HSPN.